Trial Profile

Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Ocular Hypertensive Subjects

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Latanoprostene bunod (Primary)
Indications Ocular hypertension
Focus Therapeutic Use
Sponsors Bausch & Lomb

Most Recent Events

29 Feb 2024 Planned initiation date changed from 1 Dec 2021 to 13 May 2022.
29 Feb 2024 Status changed from recruiting to withdrawn prior to enrolment.
31 Jan 2024 According to Nicox media release , Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com